PP
VERV

PDT Partners’s Verve Therapeutics VERV Stock Holding History

PDT Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-53,291
Closed -$301K – 864
2024
Q4 		$301K Sell
53,291
-128,512
-71% -$725K 0.03% 581
2024
Q3 		$880K Sell
181,803
-152,061
-46% -$883K 0.08% 394
2024
Q2 		$1.63M Buy
333,864
+143,256
+75% +$900K 0.15% 237
2024
Q1 		$2.53M Buy
190,608
+119,979
+170% +$1.59M 0.24% 146
2023
Q4 		$985K Buy
+70,629
New +$875K 0.11% 291

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PDT Partners's VERV Position: Q1 2025 in Review

PDT Partners sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 53,291 shares — an estimated $301K sold.

PDT Partners first reported a position in VERV in Q4 2023 and held it in 5 quarters. The position peaked at $2.53M in Q1 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • PDT Partners reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 53,291 Verve Therapeutics shares in Q1 2025, an estimated $301K.
  • PDT Partners first reported a position in Verve Therapeutics in Q4 2023 and held it in 5 quarters.
  • PDT Partners's Verve Therapeutics position peaked at $2.53M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.